Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 14504342.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report the clinical, echocardiographic, and pathologic findings in two patients treated with more than 5 mg of pergolide daily who developed symptomatic severe heart failure due to restrictive valvular disease. They also describe the echocardiographic data of another eight patients taking similar doses of pergolide presenting no clinical signs of heart failure. The findings suggest a possible role of high doses of pergolide in inducing restrictive valvular disease.
Medical subject headings
- Antiparkinson Agents
- Heart Valve Diseases
- Parkinson Disease
- Pergolide